83 Comments
 

Agree with this sentiment, definetly an up and coming BB

EDIT: Lmao which salty wf/ubs analysts msing this

To live is to suffer, to survive is to find some meaning in the suffering.
 

Lol I think its more the DB/UBS analysts that have been throwing MS at every single RBC BB post. Pretty sad

 

Evercore, Centerview, PJT, Barclays, JPM, Citi, RBC, tiny boutiques/restructuring shops all seem to be making strides recently.

 

Don’t forget Guggenheim, been steadily trending upwards for the past several years now

 

Not OP but IMO its just clearly the european bank most likely to survive, especially with essentially being an NYC HQ'd IB. DB and UBS are non-players, and CS has lost its grip over the last decade and seems to, from a company standpoint, value PWM/AM over IBD. That being said, I don't see Barclays reaching MS/GS/JPM level anytime soon; to even be in that discussion it needs to make some key IB hires in a few groups.

 
Most Helpful

If we speak about current momentum BofA is the big winner. If we look at the long term I would say Barclays and DB will gain the place they used to have in IB.

In any case there shouldnt be large changes in the next 5 years, expect little changes across big players. Only some boutiques will get into the EB state and others will fall off, its a matter of rainmakers changing firms for better pay conditions

 

Barclays has already proven itself - the Lehman acquisition was an amazing move. Your view of DB is interesting but I certainly agree that it has a brighter future, at least on the M&A side, compared to UBS.

I see the rising firms at JPM, BofA, and Barclays and the falling firms as UBS and perhaps Credit Suisse. I look forward to seeing how RBC(generally positive outlook), DB(generally negative outlook), and WFS(??? outlook) fare over these few years.

 

Well lets go step by step.

Bofa or baml is overhiring now due to high expectations, which means eithe layouts in the short term or getting at the level of JP/MS, one of thowe will happen for sure. This year should or at least is expected by the consensus to be good, who knows next...

JPM keeps resizing, which should be reflected on revenue in short term, but still should keep growing if they focus on key regions.

Barclays acquired Lehmsn divisions but its not what it used to be, its losing market share in some key sectors across M&A due to MDs leaving.

Credit Suisse should scale up its sponsors and TMT franchise and reorganize low profitsble cov sectors if he wants to keep strong in Europe

UBS seems to take a step back and focus on PB or UWM / PWM where they are strong leaders and revenues keep growing, not sure about their M&A franchise

 

BofA/BAML has probably the best growth trajectory out of the US BBs. Citi seems to try to do the same as them but so far BofA seems to come up on top.

JPM actually won't grow as much imo, simply because there is very little room to grow in IBD, sure maybe some more mm fees in M&A/ECM but talking to some seniors there, they are pretty saturated.

GS/MS probably mainly unchanged although outside M&A/ECM, GS seems to have a growing franchise whereas MS is pretty much unchanged (not sure the Mitsubishi thing will make a difference beyond a few mega deals)

 

I'd say GS is growing even in M&A, take a look at their cross markets initiative.

 

This is a solid point - GS is dipping heavily into midmarket business which was traditionally covered by Blair, Baird etc. A lot of business development in that area may favor GS given the brand if the client has no previous banking relationships.

 

Berenberg is on a pretty high streak atm, wouldn´t be surprised if they establish themselves as the new boutique on the block.

 

Just to speculate a bit here. Corporate leverage is pretty high these days. Energy (specifically upstream oil/gas) is an easy target, but there are pockets of other sectors drowning in debt with no real liquidity levers to pull that the market will support. With that said, I'd say any shop that does a lot of restructuring / bankruptcy emergence will probably do pretty well in the near-term.

In terms of shops: HL, Lazard, PJT, Moelis, and probably Evercore. Maybe Rothschild. I would assume bulge-brackets with strong RX desks will also reap some pretty interesting fees.

 

I like most picks mentioned. I’m actually going to take this post as a moment to criticize a bank which deserves hard criticism but never receives it and that is Goldman. Their market cap and growth numbers over recent years show underachievement. DJ D-Sol better switch up his goals.

 
"Shooter McGavin" What is the sentiment in the Middle Market? It seems shops like Baird and Blair are separating from firms such as Lincoln, Pipar, etc.

I'm not sure why people struggle to grasp this concept, but it has been talked about ad nauseam.

It depends on the group

Overall, I'd still rank the top two as HL and Blair with Piper, Baird, HW, LMM in close pursuit and top ranked in specific verticals. Lincoln isn't on the same level overall, but has some more competitive groups (HC services).

 

Would be careful with blanket statements like this. HL outside of rx is not a reputable shop and runs mostly midmarket / LMM deals depending on the group. Macquarie within investor circles is still only recognized for its MIRA practice.

 

Piper’s interesting as they’ve expanded their deal volume through organic growth, ie, Simmons Energy, Sandler and now TRS Advisors. So on the whole they’re expanding reach. On the other hand it doesn’t seem like the groups in of themselves are gaining more clout within their industries. The Sandler acq seems to be the only area where they’re actually trying to combine capabilities for better coverage in FIG.

 

Rothschild has been on a pretty big push for its US operations (m&a) the past few years. A lot of hiring at the senior level to build out new groups like fig and infra, but I'd imagine it will still be another few years for that to really manifest. They have done pretty well this year when it comes to m&a league tables (pretty easy to google search for these) but I have no idea of any specific deals. Rx is still solid and has had a few strong mandates recently like Chesapeake, subro on PG&E, but it is not the same level it used to be before Augustine left for Greenhill and Snyder left to start TRS

 

jefferies has had a record year across the board and picked up significant market share in ECM and US M&A. Still at or near the top of leveraged loan league tables as well. 

BofA is ahead of MS YTD for global IB fees. certainly noteworthy. another bank that kills it in levfin and they have capitalized on the HY bond market this year 

expect the EBs with large rx practices to continue to grow, especially guggenheim landing some big deals this year and with so much work to go around could expect to see that continue 

 

Molestias est optio qui veniam earum dolorem. Voluptatem consequatur aspernatur dicta assumenda vitae amet eligendi. Aut repellendus consequatur ipsa ipsam suscipit. Fugit nulla qui rerum velit quia.

In explicabo excepturi nobis quas et quisquam consequuntur ea. Impedit et velit incidunt dolorem aut hic. Aut et quam voluptate facere atque qui veniam eaque. Provident et et eos sed culpa. Tempora numquam deleniti animi nisi.

 

Sunt dolor dolorem provident illum. Quia voluptatem qui ducimus officiis sit quos.

Id enim voluptatem esse recusandae. Rerum laboriosam dolorum quos fuga. Iure tempora et amet et officia alias. Labore voluptas unde enim assumenda hic vitae.

Sed laborum ab sunt perspiciatis ut. Sed eos molestiae ut natus quia veritatis.

Quo aut expedita saepe ut unde ipsam praesentium eligendi. Eaque id repudiandae odit itaque ipsa omnis. Veniam est voluptatem est nostrum qui nisi quae. Consequatur soluta dicta magni et corrupti.

 

Repellat est ex est incidunt eligendi quo est. Sequi sint nobis dolor.

Error qui molestiae aspernatur voluptatem blanditiis et. Vitae quos qui suscipit enim et. Aliquam sed non nobis. Sint nihil nam mollitia porro non repellat. Id aut aliquid et minima aut omnis dolorem.

Consequatur dolorem aut quaerat perferendis consequatur minima qui incidunt. Ea iure magni soluta consequatur.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
DrApeman's picture
DrApeman
98.9
8
GameTheory's picture
GameTheory
98.9
9
CompBanker's picture
CompBanker
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”